Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

73

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

73 results for “medicinal products”

Learn how ShareScore rates datasets ↗
dryad32/100

Effect of participation in commercial production of medicinal plants through community-based conservation groups on farm income at Kakamega forest, Kenya

<p class="Abstract">Forest conservation by peripheral communities is one of the most advocated strategies for ensuring sustainable supply of forest goods and services. In Kenya, although conservation activities generate considerable environmental improvements, studies evaluating the economic benefits are very limited. This study aimed at assessing the impact of participating in the commercialization training program by forest adjacent communities on farm income. Utilizing matching techniques, the analysis is based on the data collected from a randomly selected sample of farm households around Kakamega forest in Kenya. The results show that age, forest distance, forest benefit, market distance and farming experience are the main factors that influence the participation in the commercialization program. Also, participating in commercial production of medicinal plants has a positive and significant effect on farmers' income. The average treatment effect on the treated (ATT), based on three estimation algorithms, ranges from KSH. 80,047 to KSH. 176,788 per hectare, per year, implying that policy efforts that focus on the participation in the commercialization program of medicinal plants can enhance incomes among farm-dependent households. The findings from this study suggest that upscaling the participation in the commercialization program to other areas.</p>

opencc-zeroNov 2019View details →
zenodo32/100

Development of medicinal beer production technology / Gyógysör gyártástechnológiai kidolgozása

<p>A projekt &ouml;sszetett folyamatot fed le. A kezdeti elm&eacute;leti kidolgoz&aacute;st k&ouml;vetően a f&eacute;l-&uuml;zemi megval&oacute;s&iacute;t&aacute;s, majd az &uuml;zemi l&eacute;pt&eacute;kre emel&eacute;s egym&aacute;st&oacute;l j&oacute;l elk&uuml;l&ouml;n&uuml;lő f&aacute;zisair&oacute;l besz&eacute;lhet&uuml;nk, teh&aacute;t t&ouml;bb c&eacute;l &eacute;s t&ouml;bb eredm&eacute;ny is sz&uuml;letett.&nbsp;<br>Az elm&eacute;leti r&eacute;sz &eacute;s a f&eacute;l-&uuml;zemi r&eacute;sz sikeresen, a megfogalmazott c&eacute;loknak megfelelő eredm&eacute;nnyel z&aacute;r&oacute;dott.&nbsp;<br>Az &uuml;zemi l&eacute;pt&eacute;kre emel&eacute;s a projekt z&aacute;r&aacute;s pillanat&aacute;ban nem &eacute;rte el a c&eacute;lzott eredm&eacute;nyt, hiszen a magas hozz&aacute;adott &eacute;rt&eacute;kű Kismama gy&oacute;gy-t&aacute;ps&ouml;rt, mint piack&eacute;sz term&eacute;ket nem siker&uuml;lt elő&aacute;ll&iacute;tanunk. Ugyanis a mintak&eacute;nt szolg&aacute;l&oacute; 1960-80 &eacute;vekben a Kőb&aacute;nyai s&ouml;rgy&aacute;r &aacute;ltal elő&aacute;ll&iacute;tott Nekt&aacute;r Gy&oacute;gy-t&aacute;ps&ouml;r (mint kismam&aacute;knak sz&aacute;nt tejserkentő &eacute;s energiz&aacute;l&oacute; magas &aacute;sv&aacute;nyianyag &eacute;s vitamintartalm&uacute; ital) is tartalmazott alkoholt, amit az akkori szab&aacute;lyok enged&eacute;lyeztek is, de mi a jelenlegi tudom&aacute;nyos ismereteknek &eacute;s az &eacute;rv&eacute;nyben l&eacute;vő j&ouml;ved&eacute;ki szab&aacute;lyoz&aacute;snak megfelelően az alkoholmentes funkcion&aacute;lis s&ouml;r elő&aacute;ll&iacute;t&aacute;s&aacute;t c&eacute;loztuk.&nbsp;</p> <p>A szakmai &ouml;sszefoglal&oacute; 6. pontj&aacute;ban a k&eacute;t szak&eacute;rtő, kutat&oacute;-fejlesztő munkat&aacute;rs az al&aacute;bbi k&ouml;vetkeztet&eacute;s, javaslatot fogalmazta meg az &uuml;zemi pr&oacute;bafőz&eacute;seket k&ouml;vetően:<br>&rsquo;A nekt&aacute;rs&ouml;r gy&aacute;rt&aacute;si technol&oacute;gi&aacute;j&aacute;t siker&uuml;lt adapt&aacute;lni az &uuml;zemi k&ouml;r&uuml;lm&eacute;nyek k&ouml;z&eacute;. Az elv&eacute;gzett tesztfőz&eacute;sek egy&eacute;rtelmű v&aacute;laszokat adtak az &uuml;zem &eacute;s ezzel egy&uuml;tt a benne l&eacute;vő technol&oacute;gia erőss&eacute;geire, illetve esetleges hi&aacute;nyoss&aacute;gaira. Egy term&eacute;k l&eacute;pt&eacute;kn&ouml;vel&eacute;se &uuml;zemi k&ouml;r&uuml;lm&eacute;nyek k&ouml;z&eacute; egy szisztematikusan fel&eacute;p&iacute;tett feladatsorozatot ig&eacute;nyel, amelynek vannak egy&eacute;rtelműen sikeres r&eacute;szei &eacute;s vannak olyanok, amelyeket a sok munka ellen&eacute;re m&eacute;g finom&iacute;tani kell, hogy a kialak&iacute;tott term&eacute;k az elk&eacute;pzelt minős&eacute;gben &eacute;s reproduk&aacute;lhat&oacute;an gy&aacute;rthat&oacute; legyen.&nbsp;<br>A főzőh&aacute;zi folyamatok r&eacute;szletes dokument&aacute;l&aacute;sa al&aacute;t&aacute;masztja, hogy olyan alapreceptet siker&uuml;lt &ouml;ssze&aacute;ll&iacute;tani, amely megfelel egy nekt&aacute;rs&ouml;r elv&aacute;r&aacute;sainak. Az erjeszt&eacute;s folyamat&aacute;t siker&uuml;lt &uacute;gy optim&aacute;lni, hogy szigor&uacute; technol&oacute;giai fegyelem mellett, valamint a s&ouml;rkezel&eacute;s (szűr&eacute;s, pasztőr&ouml;z&eacute;s) &eacute;s fejt&eacute;s rendelkez&eacute;sre &aacute;ll&aacute;sa mellett alkoholszeg&eacute;ny nekt&aacute;rs&ouml;r elő&aacute;ll&iacute;that&oacute;. A piaci trendek ig&eacute;nyei viszont egy alkoholmentes nekt&aacute;rs&ouml;r elő&aacute;ll&iacute;t&aacute;s&aacute;t teszik sz&uuml;ks&eacute;gess&eacute;, amely &uuml;zemszerű gy&aacute;rt&aacute;s&aacute;hoz tov&aacute;bbi optim&aacute;l&aacute;sok sz&uuml;ks&eacute;gesek az erjeszt&eacute;si oldalon. Mindenk&eacute;ppen sz&uuml;ks&eacute;ges a hőr&eacute;tegződ&eacute;s kialakul&aacute;s&aacute;nak elimin&aacute;l&aacute;sa a hidegerjeszt&eacute;si szakaszban, ugyanis a hidegerjeszt&eacute;s kezdet&eacute;n a minim&aacute;lis sz&eacute;ndioxid termelőd&eacute;s miatt nincs meg a megfelelő k&ouml;rforg&aacute;s (&ouml;nkevered&eacute;s) a tart&aacute;lyban. Tov&aacute;bb&aacute; sz&uuml;ks&eacute;ges az erjedő s&ouml;rből az &eacute;lesztő elv&eacute;tel&eacute;nek pontos idej&eacute;t meghat&aacute;rozni, amely l&eacute;p&eacute;s t&ouml;rt&eacute;nhet a rendelkez&eacute;sre &aacute;ll&oacute; szűr&eacute;si technik&aacute;val. Tov&aacute;bb&aacute; javasoljuk az alkoholtartalom alakul&aacute;s&aacute;nak egzakt, gyors nyomon k&ouml;vet&eacute;s&eacute;hez egy alkoholm&eacute;r&eacute;sre alkalmas berendez&eacute;s beszerz&eacute;s&eacute;t.&rsquo;</p> <p>A projekt szakmai &ouml;sszefoglal&oacute; jelent&eacute;s&eacute;ből kiolvashat&oacute; k&ouml;vetkeztet&eacute;sek alapj&aacute;n, a term&eacute;kkel &eacute;rdemes a j&ouml;vőben tov&aacute;bb foglalkozni, hiszen a c&eacute;l el&eacute;rhető, de ahhoz a technol&oacute;gia tov&aacute;bbi fejleszt&eacute;se sz&uuml;ks&eacute;ges. Az alkohol m&eacute;r&eacute;s&eacute;re szolg&aacute;l&oacute; berendez&eacute;s (előzetes felm&eacute;r&eacute;s alapj&aacute;n 12- 15.000.000.- Ft), m&iacute;g a hőr&eacute;tegződ&eacute;s kik&uuml;sz&ouml;b&ouml;l&eacute;s&eacute;re szolg&aacute;l&oacute; berendez&eacute;s tov&aacute;bbi tervezői egyeztet&eacute;st ig&eacute;nyel. A sz&uuml;ks&eacute;ges fejleszt&eacute;st a t&aacute;rsas&aacute;g az anyagi helyzet&eacute;nek, a piaci viszonyok helyre&aacute;ll&aacute;sa ut&aacute;n tervezett form&aacute;ban k&iacute;v&aacute;nja v&eacute;grehajtani. A jelenlegi Covid&rsquo;19 &aacute;ltal okozott glob&aacute;lis &ndash; piaci, &eacute;letviteli, stb. &ndash; neh&eacute;zs&eacute;gek normaliz&aacute;l&oacute;d&aacute;s&aacute;nak időpontja &eacute;s m&oacute;dja nem tervezhető, k&ouml;vetkezm&eacute;nyei kisz&aacute;m&iacute;thatatlanok, ez&eacute;rt a sz&uuml;ks&eacute;ges beruh&aacute;z&aacute;sokr&oacute;l a t&aacute;rsas&aacute;g k&eacute;sőbb tud d&ouml;nteni.</p> <p>&nbsp;A megszerzett tapasztalatok bizony&iacute;tj&aacute;k, hogy a know-how műk&ouml;dők&eacute;pes (hiszen az egyetemi f&eacute;l-&uuml;zemi k&iacute;s&eacute;rletek alatt el lehetett &eacute;rni a &gt;0,5 m/m % alkoholtartalmat, ez&eacute;rt a j&ouml;vőben a felt&aacute;rt hi&aacute;nyoss&aacute;gok jav&iacute;t&aacute;sa ut&aacute;n folytatnunk kell a megkezdett munk&aacute;t. Az elk&eacute;sz&uuml;lt term&eacute;kek bevezet&eacute;s&eacute;t megelőző tesztel&eacute;st, k&oacute;stoltat&aacute;st, palackoz&aacute;si, kiszerel&eacute;si k&iacute;s&eacute;rleteket, t&aacute;rol&aacute;si pr&oacute;b&aacute;kat el tudtuk v&eacute;gezni, ami szint&eacute;n pozit&iacute;vum, hiszen &iacute;gy megszerezt&uuml;k azt a tapasztalatot, amivel a majdani gy&aacute;rthat&oacute;s&aacute;g garant&aacute;lt. &nbsp;</p>

opencc-by-4.0May 2024View details →
dryad32/100

Data from: Shaping medicinal product information – a before and after study exploring physicians' perspectives on the summary of product characteristics

Objective: To establish, in the context of the revised European Pharmacovigilance Directive and based on physicians´ perspectives, how Summaries of Product Characteristics (SmPCs) could be more user-friendly and better support physicians´ interactions with patients, thereby improving patients'own understanding of their medicines. Design: Qualitative focus group discussions (step 1), development of an alternative SmPC (step 2) and an online quantitative survey (step 3) comparing the alternative SmPC to the currently approved version. Setting: Office-based physicians (n=218) from all federal states of Germany. Participants: 218 German physicians participated, with an equal representation of office-based general practitioners and specialists. For step 1 (n=18), physicians were recruited who frequently consulted SmPCs. Outcome measures: Physicians confirmed the importance of SmPCs as a comprehensive source of medicinal product information, but were moderately satisfied with the current SmPCs, utilised it infrequently and were more likely to engage additional sources of information. The alternative SmPC was consistently preferred. It differed in the way information for particular patient groups was presented, included additional sections (synopsis, checklist for patient information) and used a tabular format. Physicians indicated that SmPCs should be available with search and hyperlink functions, as well as be automatically updated and integrated in available practice software or similar solutions. Conclusions: This research contributes to the development of an official, reliable medicinal product information system meeting the needs of a modern information society while providing the reliability of an officially authorised source. In the context of health literacy, SmPCs should be established as the primary information source for health care professionals to ensure compliant and safe utilisation of medicinal products.

opencc-zeroAug 2013View details →
ClinicalTrials.gov32/100

Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158

ClinicalTrials.gov study NCT01533961. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers

ClinicalTrials.gov study NCT02758912. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

ClinicalTrials.gov study NCT02905539. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi

ClinicalTrials.gov study NCT03072030. IPD Sharing: NO. Countries: 2. Publications: 1.

closedIPD-NOFeb 2026View details →
dryad32/100

Data from: Shaping medicinal product information – a before and after study exploring physicians’ perspectives on the summary of product characteristics

Open the record for dataset details and reuse information.

publicAug 2013View details →
dryad32/100

Effect of participation in commercial production of medicinal plants through community-based conservation groups on farm income at Kakamega forest, Kenya

Open the record for dataset details and reuse information.

publicNov 2019View details →
zenodo28/100

Figure 2 from: Nykyforuk A, Fira L, Lykhatskyi P, Pyda V (2020) Experimental research of garden spinach extract as a potential anabolic medicinal product. Pharmacia 67(4): 277-282. https://doi.org/10.3897/pharmacia.67.e56880

Figure 2 The content of ceruloplasmin in the serum of rats during starvation and after the use of DESL and KO, %. Note: * – probable changes (p ≤ 0.05) between the indicators of animals of all groups before starvation and after 7 days of starvation; # – probable changes (p ≤ 0.05) between the indicators of animals of control pathology and animals that received the experimental extract and the reference drug.

opencc-by-4.0Nov 2020View details →
zenodo28/100

Figure 1 from: Nykyforuk A, Fira L, Lykhatskyi P, Pyda V (2020) Experimental research of garden spinach extract as a potential anabolic medicinal product. Pharmacia 67(4): 277-282. https://doi.org/10.3897/pharmacia.67.e56880

Figure 1 The content of TBA-active products in serum, liver and muscles of rats during starvation and after the use of DESL and KO, %. Note: * – probable changes (p ≤ 0.05) between the indicators of animals of all groups before starvation and after 7 days of starvation; # – probable changes (p ≤ 0.05) between the indicators of animals of control pathology and animals that received the experimental extract and the reference drug.

opencc-by-4.0Nov 2020View details →
zenodo28/100

Figure 1 from: Hudz N, Leontiev D, Wieczorek PP (2019) Spectral characteristics of 5-hydroxymethylfurfural as a related substance in medicinal products containing glucose. Pharmacia 66(3): 121-125. https://doi.org/10.3897/pharmacia.66.e35969

Figure 1 Spectra of 5-HMF at the concentrations of 1.97 mg/L, 3.94 mg/L, 5.91 mg/L, 7.88 mg/L, and 9.85 mg/L (Hudz et al. 2018).

opencc-by-4.0Dec 2019View details →
zenodo28/100

Supplementary material 1 from: Wang Y, Turvey ST, Leader-Williams N (2023) The scale of the problem: understanding the demand for medicinal pangolin products in China. Nature Conservation 52: 47-61. https://doi.org/10.3897/natureconservation.52.95916

TCM survey questions

opencc-zeroApr 2023View details →
ClinicalTrials.gov28/100

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

ClinicalTrials.gov study NCT04268771. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo24/100

Human birth tissue products as a regenerative medicine for post-surgical pain through multi-modal action

GEO Series GSE242389. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2024View details →
geo24/100

Analysis of transcriptomics and metabolomics reveal glutathione pathway contributed to laccase production of medicinal fungi Cerrena unicolor 87613

GEO Series GSE236542. Cerrena unicolor. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2023View details →
geo24/100

Pathway-based network medicine identifies novel natural products for Alzheimer's disease

GEO Series GSE270100. Mus musculus. 25 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenFeb 2025View details →
zenodo24/100

Figure 3 from: Hudz N, Leontiev D, Wieczorek PP (2019) Spectral characteristics of 5-hydroxymethylfurfural as a related substance in medicinal products containing glucose. Pharmacia 66(3): 121-125. https://doi.org/10.3897/pharmacia.66.e35969

Figure 3 Correlation between absorbance at 284 nm and 5-HMF concentration in the second experiment.

opencc-by-4.0Dec 2019View details →
zenodo24/100

Figure 2 from: Hudz N, Leontiev D, Wieczorek PP (2019) Spectral characteristics of 5-hydroxymethylfurfural as a related substance in medicinal products containing glucose. Pharmacia 66(3): 121-125. https://doi.org/10.3897/pharmacia.66.e35969

Figure 2 Correlation between absorbance at 284 nm and 5-HMF concentration in the first experiment.

opencc-by-4.0Dec 2019View details →
ClinicalTrials.gov24/100

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

ClinicalTrials.gov study NCT06190561. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record